Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(14)
DRUG(12)
BIOLOGICAL(1)
Ruxolitinib
4 trials
phase_1_2phase_2
john-mascarenhas
PEGASYS
3 trials
phase_1phase_2phase_3
ronald-hoffman, john-mascarenhas
Aspirin
2 trials
phase_2phase_3
ronald-hoffman
Pembrolizumab
1 trial
phase_2
john-mascarenhas
RG7388
1 trial
phase_1
john-mascarenhas
Azacitidine
1 trial
phase_1
douglas-tremblay
Selinexor
1 trial
phase_2
john-mascarenhas
Decitabine
1 trial
phase_1_2
john-mascarenhas

+13 more interventions

21 unique interventions3 categories

Analytics

Trial Phases

Phase 17
Phase 210
Phase 31

Trial Status

Completed10
Recruiting2
Terminated2
Other2

Role Distribution

Principal Investigator6
Other Roles10
PI Rate38%

Activity Timeline

Clinical Trials (16)

NCT07320235Phase 1Recruiting
Imetelstat Combinations in Relapsed AML
Relapsed Acute Myeloid Leukemia
StudychairStart date: 2026-01-02
NCT04281498Phase 2Completed
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation
StudychairStart date: 2021-01-14
NCT03895112Phase 1Completed
MPN-RC 118 AVID200 in Myelofibrosis
Post ET MFPost PV MFPost-essential Thrombocythemia Myelofibrosis+2 more
StudychairStart date: 2019-02-15
NCT03065400Phase 2Completed
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Chronic Phase MyelofibrosisPolycythemia VeraPost-essential Thrombocythemia Myelofibrosis+1 more
StudychairStart date: 2017-06-14
NCT00572897Phase 2Completed
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
Myelofibrosis
Principalinvestigator
NCT00665067Completed
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
Essential ThrombocythemiaIdiopathic MyelofibrosisMyelofibrosis+2 more
Principalinvestigator
NCT01259817Phase 2Completed
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera
Principalinvestigator
NCT01259856Phase 3Completed
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera
Studychair
NCT01291784Phase 1Terminated
Anti-TGF-beta Therapy in Patients With Myelofibrosis
MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-essential Thrombocythemia Related Myelofibrosis+1 more
Principalinvestigator
NCT01693601Phase 1/2Completed
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Myelofibrosis
Principalinvestigator

Showing 10 of 16 trials

Research Network

Collaboration Network

29 collaborators·45 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Ronald Hoffman, MD

Icahn School of Medicine at Mount Sinai

Very Similar
10 trials

Shared therapeutic areas:

Primary MyelofibrosisPolycythemia VeraThrombocythemia, Essential+12 more

Worked with same sponsors:

Celgene CorporationFormation Biologics+12 more
Collaborated on 6 trials
Similarity Score174%

Ruben Mesa, MD

Mays Cancer Center at UT Health

Very Similar
2 trials

Shared therapeutic areas:

Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation+5 more

Worked with same sponsors:

Celgene CorporationFormation Biologics+6 more
Collaborated on 2 trials
Similarity Score88%

Ruben Mesa, MD

Mayo Clinic

Similar
2 trials

Shared therapeutic areas:

Thrombocythemia, EssentialHigh Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera+2 more

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Collaborated on 1 trial
Similarity Score54%

Marina Kremyanskaya, MD, PhD

Icahn School of Medicine at Mount Sinai

Moderately Similar
3 trials

Shared therapeutic areas:

Primary MyelofibrosisChric Phase MPNThrombocythemia, Essential+1 more

Worked with same sponsors:

Incyte CorporationJohn Mascarenhas+2 more
Collaborated on 1 trial
Similarity Score44%

Gabriela Hobbs, MD

Harvard Medical School Massachussets General Hospital

Moderately Similar
1 trials

Shared therapeutic areas:

Chronic Phase MyelofibrosisPolycythemia VeraPost-Essential Thrombocythemia Myelofibrosis+1 more

Worked with same sponsors:

John MascarenhasMassachusetts General Hospital+1 more
Collaborated on 1 trial
Similarity Score44%

Rona S Weinberg, PhD

Myeloproliferative Disorders-Research Consortium

Moderately Similar
2 trials

Shared therapeutic areas:

Thrombocythemia, EssentialPrimary MyelofibrosisPolycythemia Vera+1 more

Worked with same sponsors:

Icahn School of Medicine at Mount SinaiMyeloproliferative Disorders-Research Consortium+1 more
Collaborated on 1 trial
Similarity Score44%

Michal Bar-Natan, MD

Icahn School of Medicine at Mount Sinai

Moderately Similar
1 trials

Shared therapeutic areas:

Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation

Worked with same sponsors:

Celgene CorporationIncyte Corporation+4 more
Collaborated on 1 trial
Similarity Score34%

Shivani V Handa, MD

Ohio State University

Moderately Similar
1 trials

Shared therapeutic areas:

Chric Phase MPNMPN - Accelerated or Blast PhasePrimary Myelofibrosis

Worked with same sponsors:

John MascarenhasNational Cancer Institute (NCI)+1 more
Collaborated on 1 trial
Similarity Score34%

Anthony M Hunter, MD

Emory University

Moderately Similar
1 trials

Shared therapeutic areas:

Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis

Worked with same sponsors:

John MascarenhasNational Cancer Institute (NCI)+1 more
Collaborated on 1 trial
Similarity Score34%

Abdulraheem Yacoub, MD

University of Kansas School of Medicine

Moderately Similar
1 trials

Shared therapeutic areas:

Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis

Worked with same sponsors:

John MascarenhasKaryopharm Therapeutics Inc+2 more
Collaborated on 1 trial
Similarity Score34%

Publications (0)

No publications found for this investigator.

Clinical Trials (16)

Showing 16 of 16 trials

NCT07320235Phase 1StudyChair

Imetelstat Combinations in Relapsed AML

Relapsed Acute Myeloid Leukemia
Recruiting
NCT04281498Phase 2StudyChair

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation
Completed
NCT03895112Phase 1StudyChair

MPN-RC 118 AVID200 in Myelofibrosis

Post ET MFPost PV MFPost-essential Thrombocythemia Myelofibrosis+2 more
Completed
NCT03065400Phase 2StudyChair

PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Chronic Phase MyelofibrosisPolycythemia VeraPost-essential Thrombocythemia Myelofibrosis+1 more
Completed
NCT00572897Phase 2PrincipalInvestigator

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

Myelofibrosis
Completed
NCT00665067PrincipalInvestigator

Correlative Biomarker Study in Patients With Myeloproliferative Disorders

Essential ThrombocythemiaIdiopathic MyelofibrosisMyelofibrosis+2 more
Completed
NCT01259817Phase 2PrincipalInvestigator

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera
Completed
NCT01259856Phase 3StudyChair

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera
Completed
NCT01291784Phase 1PrincipalInvestigator

Anti-TGF-beta Therapy in Patients With Myelofibrosis

MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-essential Thrombocythemia Related Myelofibrosis+1 more
Terminated
NCT01693601Phase 1/2PrincipalInvestigator

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

Myelofibrosis
Completed
NCT01790295Phase 2PrincipalInvestigator

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Post Essential Thrombocythemia MyelofibrosisPost Polycythemia Vera MyelofibrosisPrimary Myelofibrosis
Terminated
NCT02076191Phase 1/2StudyChair

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Myeloproliferative Neoplasms
Completed
NCT02407080Phase 1StudyChair

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Essential ThrombocythemiaPolycythemia Vera
Completed
NCT07447817Phase 2StudyChair

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
Recruiting
NCT07734077Phase 1/2StudyChair

Revumenib in Patients With Myelofibrosis

MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
Not Yet Recruiting
NCT07872709Phase 2StudyDirector

Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms

Chric Phase MPNMPN - Accelerated or Blast PhaseMyelofibrosis
Not Yet Recruiting

All 16 trials loaded